Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva-Barr deal complete

This article was originally published in The Tan Sheet

Executive Summary

Teva Pharmaceutical Industries' $7.5 billion acquisition of Barr Laboratories is complete, the Jerusalem-based generics firm says Dec. 23. Teva will pay an additional $1.5 in debt settlement, and receive the rights to Barr's OTC emergency contraceptive Plan B and its women's health portfolio (1"The Tan Sheet" July 21, 2008, In Brief). Under an antitrust settlement with the Federal Trade Commission announced Dec. 19, the combined entity will divest some generic drugs to Watson Pharmaceuticals and Qualitest Pharmaceuticals to complete the acquisition

You may also be interested in...



Teva buys Barr

Jerusalem-based generic drug manufacturer Teva Pharmaceuticals Industries signs an agreement to purchase Barr Laboratories, manufacturer of OTC emergency contraceptive Plan B, for $7.46 billion plus the assumption of net debt of $1.5 billion, the firms say July 18. The companies expect the deal to close in late 2008. Teva looks to the acquisition to enhance its position in the U.S. and European markets. "The combined company will have an unmatched global platform, operate directly in more than 60 countries and employ approximately 37,000 people worldwide," according to a release. Additionally, the acquisition will boost Teva's specialty pharmaceutical platform with the addition of Barr's women's health portfolio, the firms say...

Device Week, 05 March - Remote Monitoring Reimbursement, T-cell Diagnostics And A Digital Health Feature

In this week's podcast, managing editor Marion Webb discusses a new monthly digital health roundup which will soon feature on Medtech Insight. Managing editor Reed Miller discusses reimbursement difficulties as it applies to remote cardiac monitoring. UK-based reporter Barnaby Pickering gives an overview of an interview with the chief medical officer of Adaptive Biotechnologies about its new T-Detect platform.

Coronavirus Notebook: Italy Makes First Use Of EU’s Vaccine Export Control System, More Regulators Issue Guidance On Variants

Ukraine has established a system for issuing emergency use authorizations for COVID-19 vaccines that recognizes authorizations granted by other world regulators.

Topics

UsernamePublicRestriction

Register

OM008605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel